The MarketWatch News Department was not involved in the creation of this content. -- First of two Pivotal Efficacy Studies support future sNDA submission for Treatment of Pulmonary Anthrax -- Oral ...
In the event of an attack with biological weapons, would the anthrax vaccine offer protection against pulmonary anthrax, or would rapid administration of antibiotics be more efficacious? —LAWRENCE ...
BOSTON, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (PRTK) today announced positive top line data from a pilot rabbit efficacy study evaluating NUZYRA’s effectiveness in the ...
BOSTON, July 10, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving ...
Given the possible severity of anthrax infection, early and fast diagnosis is key. InBios International, Inc., a developer of diagnostic tests for emerging infectious diseases and biothreats, has been ...
Charles Nailen/The Hoya Georgetown mailroom employees who had recently been given a precautionary prescription of doxcycycline, the generic form of Cipro, have been advised by D.C. public health ...
First of two Pivotal Efficacy Studies support future sNDA submission for Treatment of Pulmonary Anthrax Oral NUZYRA Tablets Produced in the U.S. as a Result of the Company's Onshoring Initiative were ...
BOSTON, Sept. 27, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) today announced that the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of ...
KING OF PRUSSIA, Pa., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc., a privately held pharmaceutical company focused on the development and commercialization of specialty therapies ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results